Tag: GlobeNewswire

Final close of Funds 4 and 5 Series 2 takes total capital raised to full target of US$1 billion, with a 99% repeat investment rate

SYDNEY, Oct. 07, 2026 (GLOBE NEWSWIRE) — Omni Bridgeway Limited (ASX: OBL), the world’s leading alternative asset manager dedicated to legal finance, today confirmed the final close of its Funds 4 and 5 Series 2 capital raise, reaching in full the targeted US$1 billion across both funds.

The Series 2 capital raise further broadens and diversifies Omni Bridgeway’s institutional investor base, while maintaining a strong reinvestment rate. Investors representing 99% of Series 1 commitments have reinvested in Series 2, with over 50% of Series 2 capital committed by Series 1 investors. The investor base comprises global top-tier institutional investors.

The close increases assets under management to A$5.9 billion (US$4.2 billion). It comes as Omni Bridgeway marks its 40th year as a global specialist in legal assets and its 25th year listed on the ASX.

Key facts

• Strategy: Investments in legal assets, diversified globally by jurisdiction, area of law and investment style.
• Total fund size: US$1 billion across Funds 4 and 5 Series 2.
• Alignment: Approximately 20% Omni Bridgeway GP co-investment in Series 2.
• Repeat participation: Investors representing 99% of Series 1 commitments have reinvested, with >50% of Series 2 capital committed by repeat investors.
• Platform track record: As at 30 June 2026, 822 completed investments at a portfolio-wide 2.4x multiple of invested capital (MOIC) across multiple decades and economic cycles.
• Fund-level returns, vintage analysis and the Group’s forward capital strategy are set out in Omni Bridgeway’s FY26 results presentation and analyst data pack, available at omnibridgeway.com/investors.

Raymond van Hulst, Managing Director and CEO of Omni Bridgeway, said:

“In legal finance, institutional capital is consolidating around mature, scaled managers with proprietary origination and work-out capability, and a track record of disciplined underwriting that has performed through multiple economic cycles.”

“Our successful close, the 99% reinvestment rate, and the sophisticated institutional quality of our investment base reflect our leading position within legal finance.”

“Funded parties increasingly and rightly focus on capital availability, long-term stability and commitment authority. Every dollar we commit is matched by dedicated fund capital earmarked to that matter. Omni Bridgeway is the sole decision-maker, and the availability of our capital commitment is not exposed to the outcome of other portfolio investments, capital market conditions, third-party underwriting or syndication. Counterparties increasingly recognize and value these differentiators – and accordingly assign a premium to our capital.”

“The US$1 billion raised in connection with Funds 4 and 5 Series 2 sits alongside a broader capital strategy, with sidecar capital and structured finance solutions continuing to expand alongside our core funds, supporting Omni Bridgeway’s aim of further scaling and diversifying its platform.”

Investor and Media Contacts

Media

Naomi Barber, Director, Business Development & Marketing
+61 421 371 844, nbarber@omnibridgeway.com
Management is available for interviews

Investor Relations

Nathan Kandapper, Global Head of Corporate Development and Investor Relations
+61 403 941 502, nkandapper@omnibridgeway.com

ABOUT OMNI BRIDGEWAY

Omni Bridgeway is the world’s leading alternative asset manager dedicated to legal finance, with over A$5.9 billion in assets under management across multiple funds. Founded in 1986 and listed on the ASX since 2001, Omni Bridgeway has pioneered the industry and has a unique track record of consistent outperformance across multiple decades and economic cycles. With a team of approximately 160 professionals operating in over 20 locations and 15 countries, Omni Bridgeway is the largest and most diversified institutional platform for primary origination, underwriting and management of legal assets and risk, across all relevant jurisdictions and areas of law.

• Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005
• Cadrenal has received strong interest from potential strategic partners
• Cadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions

PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio.

The initiative builds on Cadrenal’s ongoing strategic partnering discussions and will evaluate a broad range of potential transactions involving the Company and its clinical- and development-stage programs, including CAD-1005, tecarfarin, frunexian, and CAD-2000, the Company’s second-generation 12-LOX platform. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions.

Cadrenal has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor in connection with the process.

“Our pipeline has reached critical clinical and regulatory maturity, anchored by our recent alignment with the FDA on the Phase 3 development pathway for CAD-1005,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “Having received strong interest from potential strategic partners, we believe a formal strategic process provides the appropriate framework to evaluate opportunities across our portfolio and determine the paths that can maximize value for our shareholders while advancing these programs for patients.”

There can be no assurance that the strategic process will result in any transaction or other strategic outcome. Cadrenal does not intend to provide updates on the process unless and until its Board of Directors approves a specific transaction or course of action, or the Company otherwise determines that disclosure is appropriate or required.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company’s portfolio comprises clinical- and development-stage programs addressing significant unmet needs in critical care cardiology and orphan cardiovascular conditions.

CAD-1005 is a first-in-class 12-lipoxygenase (12-LOX) inhibitor in development to treat heparin-induced thrombocytopenia (HIT), a serious immune-mediated thrombotic disorder. CAD-1005 is designed to selectively inhibit 12-LOX, a pathway involved in platelet immune activation and thrombo-inflammatory signaling in HIT. The program has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. Cadrenal has received FDA feedback on the pathway for a Phase 3 registration study of CAD-1005 in HIT.

Tecarfarin is a Phase 3-ready oral vitamin K antagonist under development for patients requiring chronic anticoagulation, including those with end-stage kidney disease, atrial fibrillation, and implanted left ventricular assist devices. Tecarfarin has received FDA Orphan Drug and Fast Track designations for certain indications.

Frunexian is an investigational parenteral small-molecule Factor XIa inhibitor under development for acute and critical care settings, including major cardiac surgery.

CAD-2000 is a preclinical, next-generation, orally bioavailable 12-lipoxygenase (12-LOX) inhibitor under development as an outpatient Immunology & Inflammation (I&I) platform. CAD-2000 targets adipo-inflammatory signaling and systemic lipid-driven inflammation to address chronic metabolic and cardiorenal disorders. Positioned as an oral follow-on companion to CAD-1005, the asset is optimized for broad, large-market chronic inflammatory indications, including obesity-driven systemic inflammation, metabolic-associated steatohepatitis (MASH), and chronic cardiorenal diseases. It offers potential therapeutic synergy when combined with existing blockbuster metabolic regimens. For more information, please visit www.cadrenal.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include, among other things, statements regarding the Company’s strategic process; the potential timing, structure, benefits and outcome of that process; the possibility of any licensing transaction, asset sale, partnership, business combination or other strategic transaction; the clinical development, regulatory approval and commercialization of CAD-1005, tecarfarin, frunexian, CAD-2000 and the Company’s other programs; and the potential benefits and market opportunities associated with the Company’s product candidates.

Forward-looking statements may be identified by words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

These risks and uncertainties include, without limitation, the possibility that the strategic process may not result in a transaction; the Company’s ability to identify, negotiate and complete any strategic transaction on acceptable terms or at all; potential disruption to the Company’s business during the strategic process; the Company’s need for additional capital and ability to obtain financing on acceptable terms; risks associated with clinical development and regulatory approval; the Company’s ability to develop and commercialize its product candidates; the Company’s ability to maintain the listing of its common stock on The Nasdaq Capital Market; and the other risks described under the heading “Risk Factors” in Cadrenal’s filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date of this press release, and Cadrenal undertakes no obligation to update them except as required by applicable law.

For more information, please contact:

Cadrenal Therapeutics, Inc.
Quang X. Pham, CEO
(904) 300-0701
press@cadrenal.com

TALLAHASSEE, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — Capital City Bank Group, Inc. (NASDAQ: CCBG) announced today that it will release third quarter 2026 results on Tuesday, October 20, 2026, before the market opens. Upon release, investors may access a copy of the earnings results at the Company’s Investor Relations website, investors.ccbg.com.

About Capital City Bank Group, Inc.
Capital City Bank Group, Inc. (NASDAQ: CCBG) is one of the largest publicly traded financial holding companies headquartered in Florida and has approximately $4.5 billion in assets. We provide a full range of banking services, including traditional deposit and credit services, mortgage banking, asset management, trust, merchant services, bankcards, and securities brokerage services. Our bank subsidiary, Capital City Bank, was founded in 1895 and has 62 banking offices, 27 mortgage offices and 107 ATMs/ITMs in Florida, Georgia and Alabama. For more information about Capital City Bank Group, Inc., visit www.ccbg.com. 

For Information Contact:
Jep Larkin
Executive Vice President and Chief Financial Officer
850.402.8450

Conference Call on Wednesday, October 14, 2026 at 10:30 am ET

MILTON, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) — Sono-Tek Corporation (NASDAQ: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that the Company will hold a conference call to discuss its fiscal second quarter and first half 2027 financial results, ended August 31, 2026, on Wednesday, October 14, 2026 at 10:30 am ET.

The second quarter and first half FY 2027 financial results press release will be issued before the market opens on October 14, 2026.

Conference Call Dial-in Information

To participate, please call 1-844-481-2752 or 1-412-317-0668 for international callers at least 10 minutes prior to the start of the call and ask to join the Sono-Tek call.

Webcast Information

A simultaneous webcast of the call may be accessed through the Company’s website, Events & Presentations | Sono-Tek or at:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=XwOIJQ1z

A replay of the call will be available at 1-855-669-9658 or 1-412-317-0088 for international callers, access code 9211789, through October 28, 2026. A replay of the call will also be available on the Company’s website for one year at www.sono-tek.com.

About Sono-Tek

Sono-Tek Corporation is the global leader in the design and manufacture of ultrasonic coating systems that are shaping industries and driving innovation worldwide. Our ultrasonic coating systems are used to apply thin films onto parts used in diverse industries including microelectronics, alternative energy, medical devices, advanced industrial manufacturing, and research and development sectors worldwide. Sono-Tek’s inroads into the clean energy sector are showing transformative results in next-gen solar cells, fuel cells, green hydrogen generation, and carbon capture applications. 

Our product line is rapidly evolving, transitioning from R&D to high-volume production machines with significantly higher average selling prices, showcasing our market leadership and adaptability. Our comprehensive suite of thin film coating solutions and application consulting services are expected to generate unparalleled results for our clients and help some of the world’s most promising companies achieve technological breakthroughs and bring them to the market. We strategically deliver our products to customers through a network of direct sales personnel, carefully chosen independent distributors, and experienced sales representatives, ensuring efficient market reach across diverse sectors around the globe.

Our solutions are environmentally friendly, efficient and highly reliable, and enable dramatic reductions in overspray, savings in raw material, water and energy usage and provide improved process repeatability, transfer efficiency, high uniformity and reduced emissions.

Sono-Tek’s growth strategy is focused on leveraging its innovative technologies, proprietary know-how, unique talent and experience, and global reach to further develop thin film coating technologies that enable better outcomes for its customers’ products and processes. For further information, visit www.sono-tek.com.

For more information, contact:

Sono-Tek Corp.
Stephen J. Bagley
Chief Financial Officer
Ph: (845) 795-2020
info@sono-tek.com

Investor Relations:
Kirin Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs

ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today provided an update on its strategy and progress to implement a suite of U.S. Food and Drug Administration (FDA) aligned New Approach Methodologies (NAMs) across its preclinical research and development programs, potentially enabling faster clinical advancement while significantly reducing animal testing. This strategic implementation positions VERAXA ahead of the FDA’s 2025 roadmap, which encourages the phased reduction and ultimate replacement of animal testing in favor of human-relevant, non-animal and non-clinical test methods for developing safe and effective therapies.

NAMs encompass a range of technologies, including cell-based assays, organ-on-chip systems, computational modeling and ex vivo tissue models, designed to more accurately predict human biological responses while reducing dependence on animal models. Beyond this regulatory alignment, the shift toward more sustainable and ethical research practices is also expected to reduce development costs and timelines, for example, by bypassing certain non-human primate (NHP) toxicology studies traditionally required ahead of clinical development.

“We see NAMs as not just a regulatory obligation, but also as a scientific opportunity,” said Christoph Erkel, Ph.D., Chief Scientific Officer of VERAXA. “We’ve been investing in translational, human-relevant model systems well ahead of the FDA’s 2025 roadmap, and we see this shift as beneficial and a win-win situation for both science and sustainability. Reducing our reliance on animal studies, particularly NHP toxicology testing, allows us to generate more clinically predictive data, move faster, and do so more efficiently and sustainably.”

VERAXA has been building a multi-layered panel of NAMs to characterize and de-risk its pipeline of BiTAC (bi-targeted tumor-associated cytotoxicity) based T cell engagers (BiTAC-TCEs), BiTAC-based antibody drug conjugates (BiTAC-ADCs) and bispecific antibody-drug conjugates (bsADCs) technologies. At the AACR Annual Meeting 2026, the Company presented initial data on its most advanced BiTAC-TCE program. In those studies, the candidate performed as intended in vitro and in vivo, attacking cancer cells that displayed both target molecules while sparing cells expressing only one of the two, with a safety profile that was superior, and efficacy that matched, a more traditional TCE, pointing to the possibility of a meaningfully improved therapeutic index. The in vitro results came from three-dimensional, cell line-derived spheroid models, which recapitulate solid tumor architecture more closely than two-dimensional culture. VERAXA has since generated new spheroid data demonstrating consistent predictivity of T cell engagement specificity across diverse cancer cell lines and validating the model for IND-enabling studies, further reinforcing this model’s translational value ahead of clinical development.

VERAXA further evaluated its lead BiTAC-TCE and bsADC candidates in an ex vivo panel of ten low-passage patient-derived xenograft models of non-small cell lung cancer, models that closely preserve the molecular characteristics, heterogeneity, and therapeutic response of the original tumors. Because these assays draw on tumor material from a small number of donor mice and can be split into many parallel patient samples, the panel required only about ten mice in total, versus an estimated 200 or more for comparable in vivo efficacy studies.

Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, while relevant controls, including commercial T cell engagers against non-expressed targets, showed only minimal activity, providing strong evidence that VERAXA’s dual-targeting approach extends beyond cell line models into clinically meaningful anti-tumor activity, validating the need for simultaneous dual-target engagement and reinforcing BiTAC as a next-generation approach to T cell redirection. This ex vivo platform demonstrates how VERAXA’s NAM strategy reduces both animal use and preclinical cycle time without compromising clinical relevance.

About VERAXA Biotech AG (NASDAQ: VRXA)

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based cancer therapeutics, powered by a suite of transformative technologies and guided by rigorous quality-by-design principles. The company is rapidly advancing its pipeline of conditionally active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs), and proprietary BiTAC formats into clinical development. Uniquely, VERAXA has implemented FDA-aligned New Approach Methodologies across all preclinical programs, enabling faster clinical advancement while reducing reliance on animal testing. Founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a world-renowned institution for pioneering life science research, VERAXA combines innovation with responsible research practices.

For regular updates about VERAXA Biotech, visit www.veraxa.com or follow us on LinkedIn, X (formerly known as Twitter) and Bluesky.

BiTAC® is a registered trademark of VERAXA Biotech GmbH.

Forward-looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events, or developments that VERAXA Biotech AG (the “Company”) intends, expects, plans, projects, believes, or anticipates will or may occur in the future are forward-looking statements, including the Company’s ability to utilize NAMS across its preclinical research and development programs to enable faster clinical advancement and the ability of its technological platform to produce transformative therapeutics. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this press release should be evaluated together with the many uncertainties that affect the Company’s business, particularly those identified or referenced in the risk factors section of the Company’s most recent Annual Report on Form 20-F and any subsequent reports on Form 6-K. These documents are available from the Securities and Exchange Commission, the Company website or from Company Investor Relations.

In addition, any information contained in this press release was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained in this press release and investors should not rely upon the information as current or accurate after the presentation date.

Attachment

• 20261007_VRXA_NAM_Strategy_FINAL

CONTACT: Contact
VERAXA Biotech AG – Corporate 
 Christoph Antz, Ph.D.
 Chief Executive Officer, Co-Founder
 investors@veraxa.com
 
For Media and Investors – U.S.
 Brandon Weiner
 ICR Healthcare
 VERAXA@icrhealthcare.com
 
For Media and Investors – EU
 Mario Brkulj
 investors@veraxa.com

LONDON, Oct. 07, 2026 (GLOBE NEWSWIRE) — Marex Group Limited (‘Marex’ or the ‘Group’; NASDAQ: MRX) today announces that Chair of the Board Robert Pickering has stepped down from the Group Board, having overseen an exceptional period of growth and change during his appointed three-year term.

Robert joined the Group Board in September 2021 before becoming Senior Independent Director in March 2022 and Chair of the Board in October 2023. During Robert’s tenure, Marex has undergone a period of significant growth and transformation, including its successful IPO in April 2024, and development into a leading diversified global financial services platform.

Robert has been succeeded as Chair by John Pietrowicz, a current member of the Board and Chair of the Group’s Mergers and Acquisitions Committee. John joined the Group Board in April 2024, having previously served as Chief Financial Officer of CME Group from 2014 until 2023. His extensive experience at CME, including overseeing its acquisition strategy, brings valuable expertise in financial markets infrastructure and M&A. He is also a well-known figure to the Group’s analysts and investor base. John will work closely with Robert to ensure a smooth transition.

Robert Pickering, outgoing Chair: “It has been fascinating to be part of Marex’s progression over the past five years, helping it evolve from a small private company into a Nasdaq-listed business with a market capitalization in excess of $5 billion. Marex has exciting prospects and I wish it every success in the future.”

Ian Lowitt, Group CEO: “On behalf of the Board and everyone at Marex, I would like to thank Robert for his outstanding contribution. Marex has been on an incredible journey and Robert’s experience, judgment and counsel have been invaluable. Robert guided the firm through the listing process, successful IPO on Nasdaq, and subsequent diversification and growth. We are grateful for his leadership and commitment to Marex and wish him all the very best for the future. I am excited to work with John as our new Chair as we embark on our next chapter and as we seek to extend our track record of sustainable growth.”  

About Marex: Marex Group Limited (NASDAQ: MRX) provides market access, infrastructure services and essential liquidity to clients across global commodity and financial markets. The Group provides comprehensive breadth and depth of coverage across four services: Clearing, Agency and Execution, Market Making and Hedging and Investment Solutions. It has a leading franchise in many major metals, energy and agricultural products, with access to more than 60 exchanges. Marex has over 3,400 active clients, including some of the largest commodity producers, consumers and traders, banks, hedge funds and asset managers. With more than 50 offices worldwide, the Group has over 3,000 employees across Europe, Asia and the Americas. For more information visit www.marex.com.

Enquiries please contact:
Marex: Nicola Ratchford / Adam Strachan
+44 778 654 8889 / +1 914 200 2508
nratchford@marex.com / astrachan@marex.com

FTI Consulting US / UK
+1 716 525 7239 / +44 7976870961
marex@fticonsulting.com

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the board changes and the future growth of the business. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “would,” “is/are likely to” or other similar expressions.

These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the risks discussed under the caption “Risk Factors” in our Annual Report on Form 20-F for the year-ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) and our other reports filed with the SEC. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

PHOENIX, Oct. 07, 2026 (GLOBE NEWSWIRE) — Reliance, Inc. (NYSE:RS) announced today that it will report third quarter 2026 financial results for the period ended September 30, 2026, on Wednesday, October 21, 2026, after the market closes. Reliance management will host a conference call on Thursday, October 22, 2026, at 11:00 a.m. Eastern Time. The call will be broadcast live over the Internet hosted on the Investors section of the Company’s website at reliance.com.

Reliance, Inc. Third Quarter 2026 Conference Call Details

DATE:		Thursday, October 22, 2026
TIME:		8:00 a.m. Pacific Time 10:00 a.m. Central Time 11:00 a.m. Eastern Time
DIAL-IN:		(877) 407-0792 (U.S. and Canada) (201) 689-8263 (International)
CONFERENCE ID:		13762971
WEBCAST:		https://viavid.webcasts.com/starthere.jsp?ei=1777674&tp_key=2f5a1b60e5

For those unable to participate during the live broadcast, a replay of the call will also be available beginning that same day at 2:00 p.m. Eastern Time until 11:59 p.m. Eastern Time on November 5, 2026, by dialing (844) 512-2921 (U.S. and Canada) or (412) 317-6671 (International) and entering the conference ID: 13762971. The webcast will remain posted on the Investors section of Reliance’s website at reliance.com for 90 days.

About Reliance, Inc.
Founded in 1939, Reliance, Inc. (NYSE: RS) is a leading global diversified metal solutions provider and the largest metals service center company in North America. Through a network of approximately 310 locations in 41 states and 10 countries outside of the United States, Reliance provides value-added metals processing services and distributes a full-line of over 100,000 metal products to more than 125,000 customers in a broad range of industries. Reliance focuses on small orders with quick turnaround and value-added processing services. In 2025, Reliance’s average order size was $3,120, approximately 49% of orders included value-added processing, and approximately 40% of orders were delivered within 24 hours. Reliance’s press releases and additional information are available on the Company’s website at reliance.com.

CONTACT:
(213) 576-2428
investor@reliance.com

or Addo Investor Relations
(310) 829-5400

News release

Atos awarded EcoVadis Gold Medal, ranking among the top 5% of companies assessed worldwide

Paris, France, October 7, 2026 – Atos, a global leader in AI-powered digital transformation, today announces that it has been awarded the EcoVadis Gold Medal for its sustainability performance. This recognition places Atos among the top 5% of all companies assessed by EcoVadis worldwide over the previous 12 months.

With an improved overall score of 85 out of 100, one point higher than in the previous assessment, Atos continues to demonstrate the strength and maturity of its sustainability management system. The assessment covers four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.

Atos achieved particularly strong results in Ethics, with a score of 97 out of 100, Environment, with 96 out of 100, and Sustainable Procurement, with 86 out of 100.

“The EcoVadis Gold Medal recognizes the sustained commitment of our teams to embedding sustainability across our operations and business relationships. By improving our overall score to 85 out of 100 and ranking among the top 5% of companies assessed worldwide, Atos has once again demonstrated the strength of its sustainability management system and its commitment to continuous progress across its environmental, social, ethical and responsible procurement priorities,” said Alexandra Knupe, Group Head for Corporate Social Responsibility, Atos Group.

The EcoVadis assessment is an important independent benchmark of Atos’ sustainability management system. It supports the Group’s commitment to transparent and responsible business practices and complements its broader sustainability strategy and reporting framework.

For further information on Atos Group’s sustainability commitments and performance, please refer to its latest Universal Registration Document.

###

About Atos

Atos is Atos Group’s brand dedicated to end-to-end, secure and AI-accelerated digital services. Atos designs, develops and operates digital environments that are critical to performance, resilience and sovereignty. The company helps public and private organizations around the world maintain control of their data and infrastructure, while meeting their compliance requirements.

With more than 52,000 employees serving more than 4,500 customers in 54 countries, Atos supports the modernization of IT systems, accelerates cloud and data transformation, strengthens cybersecurity and deploys secure digital workplaces for the benefit of its customers, their employees and society. Atos also offers consulting and support services through its Atos Amplify brand.

As a trusted partner in the management of complex and critical environments, Atos supports organizations in highly regulated and sovereign contexts.

About Atos Group

Atos Group is a global leader in digital transformation with nearly 54,000 employees and annual revenues of nearly €7.2 billion. With a commercial presence in 54 countries, it operates under two brands: Atos for services and Eviden for products and systems. As the European leader in cybersecurity and a leader in the cloud sector, Atos Group is committed to a secure and decarbonized future. It offers tailor-made and integrated solutions, accelerated by AI, for all sectors of activity. Atos Group is listed on Euronext Paris.

Press contact: Laurent Massicot – laurent.massicot@atosgroup.com

Attachments

• Global PR – Atos awarded EcoVadis Gold Medal, ranking among the top 5 percent of companies assessed worldwide
• EcoVadis logo

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Pollen Street Group Limited
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to Pollen Street Group Limited
(d)        Date dealing undertaken:	06th October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchases	35,964	888	888
Ordinary shares	Sales	35,964	888	888

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	07th October 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 7 OCTOBER 2026 AT 13.30 P.M. EET, MAJOR SHAREHOLDER ANNOUNCEMENT

Notification under Chapter 9, Section 10 of the Securities Market Act: Holdings of Liedon Säästöpankkisäätiö in Oma Savings Bank Plc decreased below 10 percent

On 7 October 2026, Oma Savings Bank Plc (OmaSp) received a notification under Chapter 9, Section 5 of the Securities Market Act (SMA) from Liedon Säästöpankkisäätiö (business ID 0134703-0), according to which Liedon Säästöpankkisäätiö’s holding and voting rights in OmaSp decreased below 10 percent threshold on 7 October 2026.

According to the announcement, Liedon Säästöpankkisäätiö sr owns 0 OmaSp shares, corresponding to 0 percent of OmaSp’s shares and votes.

OmaSp has one class of shares in which each share has one vote. The total number of shares is 33,356,729.

The holding of Liedon Säästöpankkisäätiö sr according to the announcement:

	% of shares and voting rights (A)	% of shares and voting rights through financial instruments (B)	Total of both in % (A+B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0	0	0	33 356 729
Positions of previous notification (if threshold crossed)	9,39	NA	9,39

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights:

Class/type of shares	Number of shares and voting rights		% of shares and voting rights
ISIN code	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI4000306733	0	0	0	0
A total	0		0

Oma Savings Bank Plc

Additional information:

Karri Alameri, CEO, tel. +358 20 758 3040, karri.alameri@omasp.fi

Distribution:

Nasdaq Helsinki Ltd
Major media
www.omasp.fi

Oma Savings Bank is a well-capitalised and profitable Finnish bank that serves over 200,000 personal and corporate customers through 48 branches across Finland and digital channels with approximately 600 experts. Oma Savings Bank’s key objective is a first-class customer experience through personal service and easy accessibility in both digital and traditional channels. Oma Savings Bank focuses primarily on retail banking and offers its customers a diverse range of banking services both through its own balance sheet and by intermediating products of its cooperation partners, such as credit, investment and loan protection products. Oma Savings Bank also engages in mortgage banking operations. The Shares of Oma Savings Bank are listed on the regulated market maintained by Nasdaq Helsinki. Oma Savings Bank is a part of S-Bank Group.